Pfizer

#Covid-19 #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

The human touch: the benefits of real world evidence

Listen to this article on the DDW Podcast: Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19. Real world evidence (RWE)  is nothing new. While clinical trials have a significant part to play  - and indeed remain the ultimate standard for… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News

#Drug delivery #Drug development #mRNA #Pfizer

Pfizer’s investment that will help speed up new medicine development

Around 85% of Pfizer's small molecule products pass through Sandwich, Kent, on their journey to market. The work of the Kent site’s team helps millions of patients globally. Brian Henry, Vice President, Drug Product Design, Medicinal Sciences provides Megan Thomas, Drug Discovery World with insight into the scientific learnings of… Read More

#Exclusive Content #News

#Antibodies #AstraZeneca #Biomedical research #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccines

Covid antibody levels vary according to vaccine type

Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccine candidate

Can Pfizer-BioNTech vaccine target the Delta variant?

Levels of antibodies in the blood of vaccinated people that can recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National… Read More

#Covid-19 #News #Trending News

#Epidemiology #Immunology / Virology & Vaccines #Pfizer

Pfizer launches Vaccine Centre of Excellence

Pfizer has launched a Centre of Excellence for Epidemiology of Vaccine-preventable Diseases at the University of Bristol. The centre, which is the second to launch to date and the first outside the US, will be led by Adam Finn, Professor of Paediatrics at Bristol, Director of the Bristol Vaccine Centre… Read More

#News #Trending News

#AstraZeneca #Clinical trials #Covid-19 #Moderna #Pfizer #Research

Behind the UK Cov-Boost trial

The UK government has begun the Cov-Boost clinical trials for a booster coronavirus vaccine in a bid to test its effectiveness against the new variants of the virus. As part of the trial, seven vaccines ordered by the UK government will be tested on thousands of volunteers at random in… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Pfizer

New President and Vice President of the ABPI announced

The UK Country Manager of Pfizer, Ben Osborn, has been appointed as the new President of the Association of the British Pharmaceutical Industry (ABPI). Pinder Sahota, General Manager of Novo Nordisk, has been appointed as Vice President. Osborn will take over from Hasseb Ahmad and will lead on overseeing… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

Evonik delivers first lipids to BioNTech ahead of schedule

Chemical specialist Evonik is helping to accelerate the production of the Covid-19 vaccine from Pfizer-BioNTech by suppling an essential component. Evonik is delivering first batches of urgently needed lipids for the mRNA-based vaccine to BioNTech months earlier than anticipated. Specialists at Evonik’s Hanau site set up the lipid production in… Read More

#Covid-19 #News

#AstraZeneca #Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pfizer

Existing vaccines may protect against coronavirus variants

Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise or stop infection from variants that are circulating in South Africa, Brazil and elsewhere. The data suggests that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly,… Read More

#Covid-19 #News

#AstraZeneca #Big pharma #Business #Covid-19 #Life sciences #Pfizer

Why investors have their eye on the pharmaceutical sector

Andrew Aldridge, Partner at  Deepbridge Capital explains why life science sector has shot up the UK investment agenda as vaccinations are rolled out. The past twelve months have showcased the importance of medical developments like never before. Innovation in the life sciences sector has been headline news around the globe and… Read More

#Business & Investment #Covid-19 #News #Opinion

#AstraZeneca #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Pfizer

COVID-19 booster shots more likely than vaccines due to variants

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been… Read More

#Covid-19 #News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Study

Study shows effectiveness of one dose of COVID-19 vaccine in over 80s

Interim study results show the effectiveness of one dose of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in preventing hospitalisation of people in their 80s with multiple comorbidities. The AvonCAP study results are by researchers from the University of Bristol, University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) and North Bristol… Read More

#Covid-19 #News